Popular Trials
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
Recruiting3 awardsPhase 4
Calgary, Alberta
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Anticoagulant
Rivaroxaban + Aspirin for Peripheral Artery Disease
Recruiting2 awardsPhase 4
Nashville, Tennessee
This trial is testing a drug that prevents blood clots in patients with poor blood flow in their arteries. The drug works by blocking a protein that helps blood to clot, which may improve their symptoms. When combined with aspirin, it has shown significant benefits in reducing deaths and heart-related problems in these patients.
Anticoagulant
Non-vitamin K oral anticoagulants (NOACs) +1 More for Atrial Fibrillation
Recruiting3 awardsPhase 2
Vancouver, British Columbia
This trial will conduct a small study to compare different blood thinners in people at risk for blood clots after open-heart surgery. The aim is to gather data to design a larger study to test the
Monoclonal Antibodies
Abelacimab vs. Rivaroxaban for Atrial Fibrillation
Recruiting1 awardPhase 2
Huntsville, Alabama
This trial is testing a new blood thinner called abelacimab to see if it causes less bleeding compared to an existing drug, rivaroxaban. It focuses on patients with atrial fibrillation who are at a higher risk of stroke. Blood thinners help prevent strokes by stopping clots, but they can also cause bleeding.
Popular Filters
Phase 3 Trials
Blood Thinner for Radial Artery Occlusion
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is testing if taking a pill after a coronary procedure can prevent artery blockage. It focuses on patients who have the procedure done through their wrist artery. The goal is to see if this pill can help keep the artery open for future use.
Anticoagulant
Rivaroxaban + Ticagrelor for Atrial Fibrillation After Stent Placement
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is testing a new combination of two drugs, ticagrelor and rivaroxaban, for patients with atrial fibrillation who have had heart artery procedures. The goal is to see if this combination can reduce the risk of heart attacks and strokes with fewer bleeding complications compared to current treatments.
Anticoagulant
Rivaroxaban for Portal Vein Thrombosis
Recruiting4 awardsPhase 3
Hamilton
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.
Trials With No Placebo
Anticoagulant
Blood Thinners for Atrial Fibrillation
Recruiting3 awardsPhase 4
Edmonton, Alberta
This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Blood Thinner for Radial Artery Occlusion
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is testing if taking a pill after a coronary procedure can prevent artery blockage. It focuses on patients who have the procedure done through their wrist artery. The goal is to see if this pill can help keep the artery open for future use.
Anticoagulant
Anticoagulants vs Antiplatelets for Blood Clot Prevention After Heart Procedure
Recruiting3 awardsPhase 4
Quebec
This trial compares two ways to prevent blood clots around a device used to treat heart problems. One is a short course of a blood thinner called a DOAC. The other is a daily antiplatelet pill.
Anticoagulant
Rivaroxaban + Ticagrelor for Atrial Fibrillation After Stent Placement
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is testing a new combination of two drugs, ticagrelor and rivaroxaban, for patients with atrial fibrillation who have had heart artery procedures. The goal is to see if this combination can reduce the risk of heart attacks and strokes with fewer bleeding complications compared to current treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.